Loading quotes...
Forecast
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
Discussions in the community
Translated from German
Sold or deleted stocks keep coming backAlready sold and/or deleted stocks that come from spin-offs or demergers keep getting re-booked. Haleon and GlaxoSmithKline I've deleted today for the 8th time. Of course, the performance is always…
Wichtel IV in Schnack 1 3Translated from German
Incorrect Booking of Haleon PLCI recently had Haleon PLC (A3DNZQ) automatically booked into my portfolio. However, after the split from GSK, I sold it immediately. Now I can't delete the booking in Parqet? Has anyone had similar…
D Daniel II in Schnack
0 2- Haleon Einbuchung auf einmal wieder da?
Hi! Mir wurden durch die Beteiligung an GSK in 2022 ein paar Haleon Aktien ins Portfolio gespült, welche ich dann im Anschluss verkauft habe. Alles auch in Parqet soweit eingepflegt. Ich habe nun…
T Timo II in Schnack
0 4 - (✅) Fehler bei GSK
Hallo, bei GSK wurde vor kurzem ein reverse split durchgeführt. Seit dem stimmen die Beträge in meinem Portfolio nicht mehr… Beim Split von Tesla war allerdings alles in Ordnung Danke für eine…
Andreas Kappes V in Schnack
0 5 - (✅) GSK Abspaltung Haleon GB00BMX86B70 nicht unterstützt
Servus, kann die Einbuchung nicht vornehmen, da GB00BMX86B70 nicht unterstützt wird.
Sven III in Schnack 6 16
News Go to news feed
Haleon cuts revenue forecast after weak cold-season quarter, shares fall
Haleon lowered its expectation for organic revenue growth in 2026 to around 2.5% (previously 3–5%) after a weak third quarter. The shares fell nearly 12% even though the adjusted operating profit outlook remained unchanged and a £500 million share buyback was announced. Headwinds included a mild cold season in North America, an export ban for Centrum in China due to a changed raw-material classification, and an accelerated distribution model in Brazil that is expected to cause Q4 sales losses of £15–20 million. A bright spot was the oral care business, with sales up 8.8%, and emerging markets sales rose 5.1%. » More on wiwo.de
Haleon publishes latest figures on share capital and voting rights
Haleon has announced that as of July 31, 2025, the company has a total of 8,987,651,560 issued ordinary shares, of which 3,880,205 are held as treasury shares. The total number of shares with voting rights therefore amounts to 8,983,771,355. This information serves as the basis for calculations in accordance with the transparency requirements of the Financial Conduct Authority. » More on de.investing.com
Haleon appoints new members to committees
Haleon has appointed Bláthnaid Bergin to the audit and risk committee and Matt Shattock to the environmental and social sustainability committee. The appointments took immediate effect and were made in accordance with UK listing rules. The announcement was published by company secretary Amanda Mellor. » More on de.investing.com
Haleon stock delivers 12.16 percent return over three years
An investment of £1,000 in Haleon three years ago would be worth £1,121.64 today, representing an increase of 12.16 percent. The calculation does not account for stock splits or dividends. Haleon was first listed on the stock exchange in July 2022 and currently has a market capitalization of £31.87 billion. » More on finanzen.net
Haleon stock delivers 9.56 percent return in one year
An investment of £100 in Haleon shares a year ago would be worth £109.56 today, representing a return of 9.56 percent. The stock was trading at £3.32 a year ago and is currently at £3.63. Haleon's market capitalization currently stands at £32.66 billion. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2025 | YoY |
|---|---|---|
| Revenue | 3.19bn | - |
| Gross profit | 2.06bn | - |
| Net profit | 469.43m | - |
| EBITDA | 811.32m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €35.89bn |
Number of shares | 8.79bn |
52-week high/low | €5.22 - €3.76 |
Dividend yield | 2.04% |
Dividends TTM | €0.0842 |
Beta | 0.24 |
P/E ratio | 18.57 |
PEG ratio | 3.16 |
P/B ratio | 1.83 |
P/S ratio | 2.66 |
Company profile
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
| Name | Haleon PLC |
| CEO | Brian James McNamara |
| Headquarters | Weybridge,
su United Kingdom |
| Website | |
| Sector | Consumer Staples |
| Industry | Personal Care Products |
| IPO | 18/07/2022 |
| Employees | 24,561 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | HLNCF |
London Stock Exchange | HLN.L |
XETRA | H6D0.DE |
Frankfurt | H6D0.F |
Düsseldorf | H6D0.DU |
Hamburg | H6D0.HM |
London | HLN.L |
München | H6D0.MU |